UNSPSC 51431503: Tirofiban

This classification denotes an antiplatelet agent with the molecular formula C22H36N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GGX234SI5H, chemically known as l-tyrosine, n-(butylsulfonyl)-o-(4-(4-piperidinyl)butyl)- but generally known as tirofiban, which bears US NIH Compound Identifier 60947. European Medicines Agency schedules Tirofiban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11118MIG.

UNSPSC 51431503 Tirofiban, a Commodity code, designates antiplatelet medications used in acute coronary syndrome and percutaneous coronary intervention — but recent state and local activity under this code shows minimal tirofiban-specific purchasing. Instead, jurisdictions are soliciting broader Advanced Life Support medications and generic multi-source pharmaceutical programs that may include tirofiban as one line item among many. The City of Tampa's April 2026 IFB for Advanced Life Support Medications (Bid No. 26-P-00188) exemplifies the scope: sealed bids for emergency medications supplied to fire rescue services, including labetalol, epinephrine, adenosine, and diltiazem, with nine-month minimum expiration dates, firm pricing including freight, and a one-year term with two optional renewals. State and local health agencies and municipalities issue opportunities under this code, typically fire rescue departments, state pharmacy benefit programs, and multistate purchasing cooperatives. Tampa Fire Rescue (within Hillsborough County, Florida) procures through the City of Tampa's Purchasing Department, while the Texas Health and Human Services Commission issued an April 2026 RFI on Direct-to-Manufacturer Prescriptions to explore pharmacy benefit program restructuring, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed to participating state and local facilities across multiple jurisdictions including Oregon.

Activity concentrates in Florida, Texas, and Minnesota based on recent postings, with MMCAP's multistate cooperative vehicle expanding the geographic reach. The Tampa IFB, posted April 24, 2026 with a due date of April 8, 2026 (note: due date precedes posting), carries an estimated contract value of $40,000 and includes a 5 percent Small Local Business Enterprise (SLBE) bid discount not to exceed $10,000; Tampa reserves the right to award by division or aggregate, cancel with ten days' written notice for cause or thirty days without cause, and extended contract options up to three additional 30-day periods. The MMCAP RFP, due March 26, 2026, sought proposals from manufacturers supplying generic pharmaceuticals through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) with awards effective July 1, 2026; vendors must maintain $5 million commercial general liability insurance and certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. The Texas RFI, due April 3, 2026, remains exploratory and does not specify budget, award timing, or formal evaluation criteria — it precedes formal RFP issuance. No tirofiban-specific awards or incumbent vendors are identified in available records.